RxDoctor Payments Data

Jed McKee, MD

Internal Medicine · Topeka, KSNPI 1699714949

Payments from drug & device makers

$513in general payments, 2019–2025

Across 41 payments — averaging $12.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$123
  • Novo Nordisk$104
  • Astellas Pharma US Inc$73
  • GSK$38
  • AbbVie$38
  • Pfizer$27
  • plus $110 from 6 others

What the payments were for

  • Food & beverage$513100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$513 in reported general payments places this provider in the 65th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$331,175
Medicare patients
690
Services billed
5,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$142,491
EliquisApixaban139$97,669
OzempicSemaglutide77$82,007
FarxigaDapagliflozin Propanediol38$49,572
TrulicityDulaglutide42$47,544
JanuviaSitagliptin Phosphate42$38,315
MyrbetriqMirabegron47$33,041
MounjaroTirzepatide28$26,498
XareltoRivaroxaban18$21,723
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$12,965
Repatha SureclickEvolocumab13$12,309
MeloxicamMeloxicam, Submicronized14$11,147
Aimovig AutoinjectorErenumab-Aooe13$9,624
Levothyroxine Sodium731$6,126
Atorvastatin Calcium765$5,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$142,491154 claims
PfizerEliquis, Paxlovid$27$100,528162 claims
Novo NordiskOzempic$104$82,00777 claims
Lilly USA, LLCTrulicity, Mounjaro$123$74,04270 claims
AstraZenecaFarxiga$25$49,57238 claims
Astellas Pharma US IncMyrbetriq$73$33,04147 claims
GSKAnoro Ellipta, Arnuity Ellipta, Breo Ellipta$38$22,88244 claims
AbbVieSynthroid$38$4,61987 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →